VTGN VistaGen Therapeutics Inc

VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (“CNS”) disorders, today announced that it will host a conference call on Thursday, August 12 at 2:00 pm Pacific Time (5:00 pm Eastern Time) to discuss its financial and operating results for its fiscal year 2022 first quarter ended June 30, 2021 and provide a business update. 

Event: VistaGen Therapeutics Fiscal Year 2022 First Quarter Financial Results Conference CallDate: Thursday, August 12, 2021Time: 2:00 pm Pacific Time (5:00 pm Eastern Time)US Dial-in (Toll Free): 1-800-935-5014Toll/International Dial-in: 1-212-231-2920Conference ID:  21996610

Shawn Singh, CEO of VistaGen, will host the conference call along with other members of the Company’s management team. The call is open to the public and will provide an update on recent developments, milestones during the first quarter of the Company’s 2022 fiscal year, which ended June 30, 2021, and certain target milestones and goals for future periods. 

A live audio webcast of the conference call will be available via this link – http://public.viavid.com/index.php?id=146257.  Participants should access this webcast site 10 minutes before the start of the call. In addition, a telephone playback of the call will be available after approximately 5:00 pm Pacific Time on Thursday, August 12, 2021. To listen to the replay, call toll free 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally (toll applies). Please use the replay PIN 21996610.

About VistaGenVistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three CNS drug candidates has a differentiated profile and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn, and Facebook.

VistaGen Company ContactsMedia:Mark McPartlandPhone: (650) 577-3606Email: IR@vistagen.com

Investors:Mark FlatherPhone: (650) 577-3617Email: IR@vistagen.com